KLRC1 Antibody - #DF4808

(1)   (5)  
Product: KLRC1 Antibody
Catalog: DF4808
Description: Rabbit polyclonal antibody to KLRC1
Application: WB IHC IF/ICC
Reactivity: Human
Mol.Wt.: 28 KD; 26kD(Calculated).
Uniprot: P26715
RRID: AB_2837159

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Clonality:
Polyclonal
Specificity:
KLRC1 Antibody detects endogenous levels of total KLRC1.
RRID:
AB_2837159
Cite Format: Affinity Biosciences Cat# DF4808, RRID:AB_2837159.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

C lectin type II protein; CD159 antigen like family member A; CD159 antigen-like family member A; CD159a; CD159a antigen; Killer cell lectin like receptor subfamily C member 1; KLRC1; MGC13374; MGC59791; Natural killer cell lectin; Natural killer cell protein group 2-A1; Natural killer cell receptor NKG2A; Natural killer group protein 2; NK cell receptor A; NKG2 1/B activating NK receptor; NKG2 A; NKG2 A/B activating NK receptor; NKG2 A/B type II integral membrane protein; NKG2 A/NKG2 B type II integral membrane protein; NKG2; NKG2 B; NKG2-1/B activating NK receptor; NKG2-A/B-activating NK receptor; NKG2-A/NKG2-B type II integral membrane protein; NKG2A; NKG2A_HUMAN; NKG2B; rNKG2A;

Immunogens

Immunogen:
Uniprot:

P26715(NKG2A_HUMAN) >>Visit HPA database.

Gene(ID):
KLRC1(3821)
Expression:
P26715 NKG2A_HUMAN:

Natural killer cells.

Sequence:
MDNQGVIYSDLNLPPNPKRQQRKPKGNKNSILATEQEITYAELNLQKASQDFQGNDKTYHCKDLPSAPEKLIVGILGIICLILMASVVTIVVIPSTLIQRHNNSSLNTRTQKARHCGHCPEEWITYSNSCYYIGKERRTWEESLLACTSKNSSLLSIDNEEEMKFLSIISPSSWIGVFRNSSHHPWVTMNGLAFKHEIKDSDNAELNCAVLQVNRLKSAQCGSSIIYHCKHKL

PTMs - P26715 As Substrate

Site PTM Type Enzyme
Y8 Phosphorylation
Y40 Phosphorylation
T89 Phosphorylation
S104 Phosphorylation
S105 Phosphorylation
T108 Phosphorylation
T110 Phosphorylation
K195 Acetylation
K199 Acetylation

Research Backgrounds

Function:

Plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells.

Subcellular Location:

Membrane>Single-pass type II membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Natural killer cells.

Subunit Structure:

Can form disulfide-bonded heterodimer with KLRD1. KLRD1-KLRC1 heterodimer interacts with peptide-bound HLA-E-B2M heterotrimeric complex.

Research Fields

· Human Diseases > Immune diseases > Graft-versus-host disease.

· Organismal Systems > Immune system > Antigen processing and presentation.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

References

1). Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy. Frontiers in Cell and Developmental Biology, 2021 (PubMed: 34368124) [IF=5.5]

Application: IHC    Species: Human    Sample: UCEC tumor and the adjacent tissues

FIGURE 4 The mRNA and protein expression level of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues. (A,B) The mRNA expression of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues. (C,D) The protein expression of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues observed using IHC.

Application: IHC    Species: Human    Sample: UCEC tumor and the adjacent tissues

FIGURE 4 The mRNA and protein expression level of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues. (A,B) The mRNA expression of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues. (C,D) The protein expression of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues observed using IHC.

Application: IHC    Species: Human    Sample: UCEC tumor and the adjacent tissues

FIGURE 4 The mRNA and protein expression level of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues. (A,B) The mRNA expression of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues. (C,D) The protein expression of CCL13 and KLRC1 in UCEC tumor and the adjacent tissues observed using IHC.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.